High-purity Bronchogen (Ala-Asp-Glu-Leu) is a synthetic short bioregulator peptide investigated for its capacity to modulate bronchial epithelial integrity, gene expression, and vascular permeability in preclinical models of mucosal edema. PX1 Research serves as a premier USA-based manufacturer and supplier, delivering analytical-grade compounds backed by lot-specific mass spectrometry, HPLC purity assays, and stringent endotoxin testing for institutional laboratory research.
High-purity Bronchogen (Ala-Asp-Glu-Leu) is a synthetic short bioregulator peptide investigated for its capacity to modulate bronchial epithelial integrity, gene expression, and vascular permeability in preclinical models of mucosal edema. PX1 Research serves as a premier USA-based manufacturer and supplier, delivering analytical-grade compounds backed by lot-specific mass spectrometry, HPLC purity assays, and stringent endotoxin testing for institutional laboratory research.
A professional manufacturer of Bronchogen for mucosal edema research provides synthetic Ala-Asp-Glu-Leu (ADEL) tetrapeptide synthesized under strict quality controls, offering verified purity exceeding 98-99% alongside complete analytical validation including RP-HPLC, mass spectrometry, and endotoxin assays.
In laboratory investigations, mucosal edema represents a key pathological feature of chronic airway inflammation, characterized by microvascular leakage, submucosal fluid accumulation, and impaired epithelial barrier function. Researchers evaluating short Khavinson bioregulator peptides require consistent, highly characterized material to measure changes in gene expression, cell proliferation, and structural protein synthesis in vitro and in animal models. PX1 Research manufactures Bronchogen peptide in US-based facilities, guaranteeing batch-to-batch consistency and rigorous quality standards essential for reproducible scientific inquiry.
Bronchogen is a synthetic short peptide composed of four amino acids: L-Alanine, L-Aspartic Acid, L-Glutamic Acid, and L-Leucine (Ala-Asp-Glu-Leu). Categorized within the class of peptide bioregulators initially identified in organ-specific tissue extracts, short peptides like Bronchogen are hypothesized to interact directly with targeted chromatin regions, modulating transcriptional activity in bronchial epithelial cells.
In vitro assays demonstrate that short amino acid sequences can penetrate cell membranes and nuclear structures, binding to specific DNA motifs within gene promoter regions. This molecular interaction alter histone acetylation profiles and chromatin accessibility, promoting the expression of cytokeratins and surfactant proteins critical for bronchial mucosal integrity. When evaluating pulmonary tissue degradation, researchers utilize analytical-grade compounds from specialized facilities to ensure that non-specific peptide fragments or synthesis impurities do not confound cellular signaling readouts.
By stabilizing the structural apparatus of airway epithelial layers, Bronchogen is studied for its role in modulating local cytokine cascades and preserving cellular junction complexes. Understanding these molecular dynamics requires compounds produced via solid-phase peptide synthesis (SPPS) with precise sequence fidelity, available through the PX1 research library hub.
Mucosal edema in bronchial tissues occurs when inflammatory cascades disrupt the delicate balance between microvascular fluid filtration and lymphatic drainage. In preclinical airway inflammation models—such as ovalbumin-sensitized rodents or lipopolysaccharide (LPS)-induced pulmonary challegens—proinflammatory cytokines including IL-4, IL-5, IL-13, and TNF-alpha trigger endothelial cell retraction, mucosal hyperreactivity, and basement membrane remodeling.
This microvascular disruption leads to extravasation of plasma proteins into the interstitial submucosa, causing tissue swelling, goblet cell hyperplasia, and compromised gas exchange capacity. Preclinical studies suggest that interventions targeting gene expression within bronchial epithelial cells may assist in regulating endothelial tight junction proteins (such as occludin and claudins), thereby reducing vascular hyperpermeability and fluid accumulation.
Investigating these mechanisms requires highly characterized research compounds. Scientists studying the systemic or local application of bioregulators analyze markers such as bronchoalveolar lavage fluid (BALF) protein concentrations, myeloperoxidase (MPO) activity, and histopathological scoring of mucosal thickening to quantify anti-edematous activity.
Preclinical investigations into Bronchogen have evaluated its physiological impact across various animal models of acute and chronic pulmonary dysfunction. In rodent models exposed to toxic inhalants or inflammatory agents, administration of Bronchogen demonstrated a statistically significant reduction in inflammatory cell infiltration and submucosal edema compared to untreated controls.
In vitro data indicate that primary bronchial epithelial cultures treated with Bronchogen exhibit altered expression profiles of markers associated with cellular differentiation and repair. Specifically, short-chain peptide bioregulators have been observed to decrease the production of pro-inflammatory interleukins while restoring normal ciliary beat frequency and mucus clearance kinetics in compromised cell lines.
Furthermore, comparative research published in organotypic culture studies highlights the tissue-specific activity of Bronchogen. While broader immunomodulatory peptides operate across generalized immune pathways, Bronchogen shows targeted binding affinity and transcriptional influence within lung parenchymal and bronchial mucosal tissues. Researchers can explore complementary compounds across our complete catalog of research peptides to compare organ-specific regulatory mechanisms.
Understanding the distinct roles of synthetic bioregulators is crucial when designing multi-arm preclinical protocols. Bronchogen belongs to a broader family of short peptide sequences engineered to target specific tissue types and physiological systems.
While Bronchogen specifically targets bronchial tissue remodeling and mucosal fluid balance, Vilon bioregulator (Lys-Glu) is primarily studied for its generalized immunomodulatory effects and T-cell regulation. Similarly, Epitalon peptide (Ala-Glu-Asp-Gly) focuses on pineal gland activity, telomerase activation, and neuroendocrine regulation. For researchers evaluating vascular signaling and tissue repair in broader barrier tissues, compounds like BPC 157 peptide offer contrasting mechanisms centered on VEGFR2 pathways rather than direct chromatin-level gene transcription. Selecting the appropriate bioregulator depends on whether the investigative model emphasizes organ-specific epithelial integrity or systemic physiological signaling.
Sourcing Bronchogen for high-precision laboratory experiments requires evaluating candidate manufacturers against stringent analytical criteria. Substandard synthesis can introduce truncated peptide sequences, residual organic solvents, or bacterial endotoxins that invalidate experimental assays.
PX1 Research maintains advanced US-based manufacturing protocols utilizing automated Solid-Phase Peptide Synthesis (SPPS). Every batch of Bronchogen undergoes rigorous analytical testing in ISO 17025 accredited facilities. High-Performance Liquid Chromatography (RP-HPLC) verifies peptide purity levels above 98-99%, ensuring that target sequence identity is strictly maintained without contaminating side-products.
Mass Spectrometry (MS) confirms exact molecular mass and sequence alignment, eliminating ambiguity regarding peptide integrity. Crucially for mucosal and immune-cell research, PX1 performs quantitative Chromogenic LAL Endotoxin Testing to ensure levels remain well below established research thresholds (<0.01 EU/mg). Every shipment includes a lot-specific Certificate of Analysis (COA) containing raw HPLC chromatograms and mass spectra data.
To preserve the structural stability of lyophylized Bronchogen tetrapeptide in laboratory environments, strict reconstitution and storage guidelines must be followed.
Reconstitution should be performed using sterile Bacteriostatic Water or sterile 0.9% Sodium Chloride Injection, depending on the specific requirements of the in vitro or in vivo model. Solvent should be allowed to run down the inner wall of the glass vial rather than injected directly onto the lyophilized cake, followed by gentle swirling. Mechanical vortexing or vigorous shaking must be avoided to prevent peptide shear or aggregation.
Lyophilized vials should be stored at -20°C for long-term stability, protected from light exposure. Reconstituted solution aliquots should be used immediately or stored at -80°C to prevent freeze-thaw degradation cycles. Detailed handling and storage parameter documentation is detailed in our dedicated Bronchogen research guide.
Securing a resilient, transparent supply chain is essential for academic institutions, biotechnology companies, and contract research organizations (CROs). Sourcing compounds from overseas suppliers often introduces risks related to temperature excursions during transit, variable customs delays, and unverified batch quality.
PX1 Research operates dedicated manufacturing and dispatch centers within California and Arizona. This domestic footprint ensures rapid order fulfillment, including same-day dispatch for orders finalized before standard cutoff times Monday through Friday. Temperature-controlled packaging protects lyophilized peptide integrity throughout shipping.
By controlling synthesis, purification, analytical testing, and fulfillment within the USA, PX1 eliminates supply chain bottlenecks and guarantees consistent batch-to-batch quality. Laboratories engaged in ongoing research projects can rely on uniform compound specifications across multi-year experimental series.
Principal investigators and laboratory managers requiring high-volume peptide supplies for large-scale preclinical trials benefit from customized institutional procurement programs.
PX1 Research provides scalable bulk ordering options, customized vial sizing, and dedicated account management for academic and commercial institutions. Bulk orders undergo identical analytical verification—including comprehensive lot COAs and endotoxin screening—ensuring seamless scalability from small pilot studies to full preclinical programs. Facilities interested in establishing recurring procurement pipelines can apply directly through our wholesale lab portal.
What is Bronchogen studied for in preclinical models?
Bronchogen is studied in preclinical research for its effects on bronchial epithelial cell differentiation, chromatin modulation, mucosal edema reduction, and repair of damaged respiratory tissues in vitro and in animal models.
How does Bronchogen target bronchial mucosal edema?
Preclinical data suggest Bronchogen (Ala-Asp-Glu-Leu) interacts with nuclear chromatin in lung tissue to modulate gene transcription, support epithelial tight junction integrity, and reduce microvascular fluid leakage into the submucosa.
What purity standard is required for laboratory Bronchogen research?
Analytical-grade research requires peptide purity of 98% or higher, verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS), to ensure reproducible experimental results.
Why is endotoxin testing critical for Bronchogen mucosal edema studies?
Bacterial endotoxins can independently induce vascular permeability, airway inflammation, and mucosal swelling. Ensuring endotoxin levels are verified below 0.01 EU/mg prevents false positive readouts in preclinical edema assays.
Is Bronchogen approved for human clinical use or therapy?
No. Bronchogen is strictly a research-grade chemical compound intended for in vitro and laboratory research use only. It is not approved for human consumption, clinical treatment, or diagnostic applications.
How should lyophilized Bronchogen be stored upon delivery?
Lyophilized Bronchogen should be stored at -20°C in a dry, dark environment. Once reconstituted, solution aliquots should be kept at -80°C to maintain structural stability and minimize degradation.
How does Bronchogen compare to Vilon or Epitalon?
Bronchogen specifically targets bronchial epithelial and mucosal tissue structures, whereas Vilon focuses on generalized immune and T-cell modulation, and Epitalon regulates neuroendocrine and telomerase activity.
What documentation accompanies PX1 Research Bronchogen orders?
Every lot of PX1 Research Bronchogen includes a comprehensive Certificate of Analysis (COA) detailing RP-HPLC purity chromatograms, Mass Spectrometry sequence verification, and quantitative LAL endotoxin data.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.